14th Jul 2020 20:12
NetScientific PLC - the healthcare IP commercialisation company - Says its portfolio company PDS Biotechnology Corp announced that PDS Biotech collaborator has been awarded a grant from the National Institute of Allergy & Infectious Diseases' Collaborative Influenza Vaccine Innovation Centers program to progress development of a Versamune-based universal influenza vaccine. The key objective of the program is to develop more durable, broadly protective, and longer-lasting vaccines effective against multiple strains of influenza, specifically including pandemic strains. Under the award, PDS Biotech will continue development of its PDS0202 vaccine program, which combines Versamune with novel influenza vaccine antigens, with a goal of rapidly progressing into a human clinical trial. NetScientific holds 7.2% of PDS' undiluted share capital.
Current stock price: 4.85 pence
Year-to-date change: down 28%
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Netscientific